A Parallel-group, Prevention, Phase III, Modified Double-blind, 2-arm, Study to Investigate the Immunogenicity and Describe the Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared With Nimenrix® When Administered in a 1+1 Schedule in Healthy Infants and Toddlers at 6 and 12 Months of Age
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi; Sanofi Pasteur
Most Recent Events
- 27 Feb 2025 Planned End Date changed from 12 Aug 2025 to 3 Oct 2025.
- 27 Feb 2025 Planned primary completion date changed from 10 Mar 2025 to 3 Oct 2025.
- 27 Feb 2025 Status changed from recruiting to active, no longer recruiting.